Achieve is a privately held specialty pharmaceutical company committed to advancing cytisine as a widely available treatment option to help people battling nicotine addiction. In January 2017, Achieve entered into a definitive merger agreement with OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) to create a global, clinical-stage company focused on development and commercialization of cytisine. To learn more about our company, please review our investor presentation.
Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 15 years. It is estimated that over 20 million people have used cytisine to help combat nicotine addiction, including approximately 2,000 patients in Phase 3 clinical trials conducted in Europe and New Zealand and published in the New England Journal of Medicine.